Welcome to our dedicated page for Thc Therapeutics news (Ticker: THCT), a resource for investors and traders seeking the latest updates and insights on Thc Therapeutics stock.
THC Therapeutics, Inc. (THCT) generates news that reflects its evolution from a technology-focused cannabis company into a portfolio operator in the legal and regulated cannabis industry. Company press releases highlight acquisitions, strategic agreements, product development milestones, and shifts in business strategy.
Recent news emphasizes THCT’s roll-up strategy in cannabis. The company has announced the acquisition of The Headquarters Group, Inc., a Medford, Oregon–based holding company with subsidiaries in genetics, cultivation, extraction, distribution, nutrients, and cannabis-related real estate. It has also reported acquiring STHoldings Group LLC, the parent of SugarTop Buddery, a vertically licensed cannabis company based in Eugene, Oregon with operations across cultivation, processing, wholesale, and retail.
Earlier releases focus on the development of THCT’s patented dHydronator® sanitizing herb dryer, including completion of the consumer model design, work on a commercial model, and laboratory testing to validate drying and sanitizing performance. Other announcements describe consulting and advisory relationships intended to identify acquisition targets in cannabis and psychedelics, explore modern healthcare-related opportunities, and support investor relations and corporate communications.
Investors and observers following THCT news can expect updates on acquisitions and portfolio expansion, progress related to the dHydronator® technology, exploratory initiatives such as a proposed THCT Silver precious metals subsidiary, and strategic partnerships in cannabis, wellness, and related industries. This news feed offers a centralized view of how THC Therapeutics presents its business direction, portfolio development, and strategic priorities over time.
THC Therapeutics (OTC:THCT) has acquired SugarTop Buddery's parent company STHoldings Group LLC in an all-share transaction valued at $3 million, paid entirely through Series D Preferred stock. This marks THCT's second strategic acquisition following The Headquarters Group purchase in June 2025.
SugarTop Buddery, a female-founded Oregon cannabis brand established in 2015, generated $2.1 million in revenue in 2024, down from its peak of $4.3 million in 2022. The acquisition includes STB Enterprises LLC, STIP (intellectual property), and STH Enterprises LLC (hemp subsidiary).
The deal strengthens THCT's presence in Oregon and advances its bi-coastal, vertically integrated cannabis platform strategy while adding a culturally significant brand known for music collaborations, pre-rolls, and social equity initiatives.
THC Therapeutics (OTC:THCT) has acquired The Headquarters Group (THG) in an all-share transaction valued at $11 million, paid through 11,007 thousand shares of newly created Series D Preferred stock. THG operates a portfolio of cannabis companies spanning genetics, cultivation, extraction, distribution, specialty real estate, and nutrients, with combined revenue of $4.8 million.
The acquisition unites companies with over 60 years of combined cannabis industry experience, establishing THCT's presence in California and Oregon markets. The deal aims to create a vertically integrated cannabis platform, with potential for expansion into other U.S. and international markets. THG has been operating in the cannabis industry since 2001, and under the transaction, THCT and current THG operators will assume management control.
THC Therapeutics, Inc. (THCT) has entered a consulting agreement with Five Points Consulting to pursue growth opportunities in the Cannabis and Psychedelics sectors. CEO Kevin Bell, with extensive experience in cannabis mergers and acquisitions, aims to enhance company value through strategic acquisitions. Founder Brandon Romanek expressed excitement about the partnership, noting its potential impact on THCT. The company is also focused on its patented dHydronator, designed to significantly reduce cannabis drying time.
THC Therapeutics, Inc. (THCT) has secured an agreement with Shefford Capital Partners for up to $50 million in funding aimed at acquisitions in the cannabis and alternative therapies sectors. The deal includes $25 million in restricted shares and $25 million in debt financing. This capital will support THCT's strategy to acquire established companies within the cannabis industry and modern healthcare. The favorable terms, akin to those available to larger market-listed firms, mark a significant advancement for THCT and its mission to become a leader in cannabis and health-related mergers and acquisitions.
THC Therapeutics, Inc. (THCT) has appointed Jonathan Cross as the new Chief Financial Officer, leveraging his 33 years of experience in finance and mergers and acquisitions. Cross aims to enhance shareholder value and develop a finance team focused on transparency and accountability. He plans to refine the company's strategy, including the ongoing development of the dHydronator, a device that accelerates cannabis drying. Under CEO Brandon Romanek, the company is also exploring entry into the psychedelics market, aiming to solidify its position in the cannabis industry.
THC Therapeutics, Inc. (THCT) is considering entering the precious metals sector by establishing a subsidiary named THCT Silver for online retail of silver bullion. The company has been accumulating silver since February 2021 and aims to sell silver to publicly traded companies, providing them an opportunity to diversify cash holdings. CEO Brandon Romanek, with over 15 years of experience, believes that this strategy addresses market manipulation and fosters demand for silver. The strategy is a potential revenue growth avenue, leveraging increasing retail interest in silver.
THC Therapeutics (THCT) has signed a contract with Dr. Jesse Dean to onboard well-known cannabis celebrities to its board of directors. This agreement aims to enhance THC Therapeutics' marketing strategy for its dHydronator technology. Dr. Dean's contract includes 2.3 million shares and warrants that could generate $4.5 million if exercised. CEO Brandon Romanek expresses enthusiasm about the potential celebrity partnerships that Dr. Dean can bring. The dHydronator aims to revolutionize cannabis drying, significantly reducing drying time from 10-14 days to under 14 hours.
THC Therapeutics, Inc. (THCT) has completed the design phase for the consumer model of its patented dHydronator®. This product, aimed at the cannabis market, significantly reduces drying time from two weeks to less than 14 hours while sanitizing the product. The company is now seeking manufacturing partners and is in the pre-production phase. THC Therapeutics plans to enhance its patent claims as the commercial model design progresses. CEO Brandon Romanek emphasizes the importance of this step as they engage with strategic partners for future growth.
THC Therapeutics, Inc. (THCT) has finalized the consumer model design for its patented dHydronator®, a cannabis sanitizing dryer, now entering rapid prototyping for mass manufacturing. Following extensive market research by Keyhole Research, the company has also initiated the search for a manufacturing partner. The dHydronator® can reduce cannabis drying time to 10-14 hours while sanitizing the product efficiently, validated through independent testing. Additionally, the company aims to expand its patent protections and develop a commercial model of the device.
THC Therapeutics, Inc. (THCT) announced its partnership with Milestone Management Services to enhance corporate communications and investor awareness. Milestone's CEO emphasized the growing investor interest in sectors like cannabis and technology. Brandon Romanek, CEO of THCT, highlighted that this collaboration will improve deal flow and capital raising efforts. The company is leveraging its patented dHydronator technology, which significantly reduces cannabis drying time, and is actively seeking strategic partnerships to increase shareholder value.